Navigation Links
Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments
Date:9/24/2008

Lilly CEO Lechleiter detailed registry plans at Indianapolis speech

INDIANAPOLIS, Sept. 24 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) announced that it is set to become the first pharmaceutical research company to disclose its payments to physicians in the United States.

At a speech before the Economic Club of Indiana today, Lilly's president and chief executive officer, John Lechleiter, Ph.D., outlined the company's plans to launch an online registry of physician payments in 2009. Lechleiter announced the physician registry as a part of a broader outline on the company's transformation efforts.

"With each of our industry firsts, from launching our clinical trials registry to the public reporting of educational grants, Lilly is striving to be a leader in improving transparency across our industry," said Lechleiter. "As Lilly continues to look for more ways to be open and transparent about our business, we've learned that letting people see for themselves what we're doing is the best way to build trust."

Earlier this year, Lilly was the first pharmaceutical research company to endorse bipartisan federal legislation - known as the Physician Payments Sunshine Act - that would establish a national registry of payments to physicians by medical device, medical supply and pharmaceutical companies. The legislation, which was introduced by United States Senators Charles Grassley (R-Iowa) and Herbert Kohl (D-Wisconsin) last September, has not been passed yet by Congress.

Lechleiter added, "Though we remain hopeful that the Sunshine Act will be passed by Congress at some point, Lilly is taking action independently. Being more transparent by opening up our business to the public is an important step to building trust and confidence."

Under the Lilly registry plan, the public will have access to an Internet database listing its payments to physicians. Lilly will launch this registry as early as the second half of 2009. When first launched, its contents will include 2009 payments to physicians who serve the company as speakers and advisors. By 2011, Lilly plans to expand the reporting capabilities of the registry to resemble the Sunshine Act legislation. The registry will be updated annually to reflect the previous year's payment information.

"Eli Lilly is leading the charge for transparency in the relationship between pharmaceutical companies and doctors by fulfilling the obligations of the Physician Payments Sunshine Act before it has been enacted," said Senator Kohl. "It takes a lot of courage to be the first. They have made a principled decision that I believe will benefit both their business and the consumers of their products."

"Lilly is proud of the important and longstanding relationships we have with physicians," said Lechleiter. "Many physicians perform valuable services for the biopharmaceutical industry by advising us on the development of new medicines and giving lectures to other medical professionals to educate them about new treatment options. For these services, they are compensated at market rates. These services help to advance the science related to medicines and are important to both current and future patients who rely on pharmaceuticals as an integral part of their therapy."

"Our primary focus is the well-being of our patients and APA has adopted strict disclosure policies to ensure our patients are informed regarding relationships between physicians and industry," said James H. Scully Jr., M.D., CEO and Medical Director of the American Psychiatric Association. "We applaud efforts by Lilly to ensure there is transparency in their relationships with physicians."

Lilly's plan to create a physicians payments registry is consistent with other voluntary actions it has taken recently to enhance transparency in health care, including its support of the Physician Payments Sunshine Act. In 2004, Lilly became the first company to voluntarily make public its clinical trials and its clinical trials data; that information can be found at http://www.lillytrials.com. Last year Lilly added another first by publicly reporting all of its educational grants and charitable contributions and, each quarter, posting the data online at http://www.lillygrantoffice.com.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. C-LLY


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly and Amylin Set Date and Time for Conference Call
2. Covance and Lilly Enter Into a Strategic R&D Collaboration
3. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
4. Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country
5. Lilly Partners With the National Council of La Raza to Fight Chronic Disease
6. Lilly Supports Industry Code on Interactions with Healthcare Professionals
7. AUDIO from Medialink, Eli Lilly and the American Association of Clinical Endocrinologists: Dont let Natural Disasters Leave you Without Needed Medications
8. Lilly Declares Third-Quarter Dividend
9. Lilly to Provide Aid to Indiana Tornado and Flood Victims
10. Lilly Announces Changes in Key Leadership Roles
11. AUDIO from Medialink and Eli Lilly and Company: F.A.C.E. Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
(Date:5/26/2016)... CT; Scottsdale, AZ (PRWEB) , ... ... ... insights consultancy, Actûrus , is happy to announce the launch of ... thinking of the funnel model to reflect the dynamic landscape of modern ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film ... FCPX. , "This new layered style transition tool will keep a consistent flow to ... of Pixel Film Studios. , TranSweep is an all new layered style transition ...
(Date:5/26/2016)... Madeira Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... island connected to the mainland by a single drawbridge, citizens formed an organization, Madeira ... increase already congested traffic and change the small town center to a high rise ...
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, a hippie is ... beauty products, one company is going against the norm with a line of all-natural ... star in the green space is proud to announce its latest retail partnership with ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology: